MannKind (MNKD) and Tolero Pharmaceuticals announce a license agreement granting Tolero...

|About: MannKind Corporation (MNKD)|By:, SA News Editor

MannKind (MNKD) and Tolero Pharmaceuticals announce a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MNKD's Bruton's tyrosine kinase program for the treatment of hematological malignancies and inflammatory diseases. MNKD +7.1% premarket.